Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma (pages 3187–3192)
Weijing Sun, Davendra Sohal, Daniel G. Haller, Kristine Mykulowycz, Mark Rosen, Michael C. Soulen, Millie Caparro, Ursina R. Teitelbaum, Bruce Giantonio, Peter J. O'Dwyer, Abraham Shaked, Rajender Reddy and Kim Olthoff
Article first published online: 24 JAN 2011 | DOI: 10.1002/cncr.25889
Anti-angiogenesis agents have shown effectiveness in treatment of hepatocellular carcinoma (HCC). The combination of bevacizumab, oxaliplatin, and capecitabine showed encouraging results in both effective and safe profiles in treatment of patients with advanced unresectable and untransplantable HCC, especially in those patients with suboptimal performance status and liver function.